Latigo Biotherapeutics Inc.
NASDAQ:LTGOMedical - Pharmaceuticals
+$0.76 today
- Market cap
- $800.64M
- Beta
- 0.00
Volume 0.21M
Average 0.38M
LTGO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Depreciation & Amortization history
Currency unavailable · from the cash flow
No Depreciation & Amortization data reported for this period type.
Depreciation & Amortization vs competitors
How LTGO compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $227.86M USD | +19.7% | +16.7% | 28.6% | |
| LTM Mar 2026 | $91.19M USD | +11.8% | -0.2% | 12.4% | |
| LTM Mar 2026 | $6.49M USD | +61.5% | +5.3% | 19.2% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — | — |
| Peer median (excluding LTGO) | — | +19.7% | +5.3% | 19.2% | |
Competitors are the stored peer set for LTGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Latigo Biotherapeutics Inc.
NASDAQ:LTGO
Intrinsic Alpha fair value
Locked
Current Price
$13.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.